G1 Therapeutics First Quarter 2024 Earnings: Revenues Disappoint [Yahoo! Finance]
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
G1 Therapeutics and Pepper Bio sign license agreement for lerociclib [Seeking Alpha]